Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)
November 08 2019 - 02:07PM
Edgar (US Regulatory)
Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended
Registration Statement No. 333-229882
Supplementing the Preliminary Prospectus Supplement, dated November 8, 2019
(To Prospectus dated February 26, 2019)
Zimmer Biomet Holdings, Inc.
Pricing Term Sheet
500,000,000 1.164% Notes due 2027
November 8, 2019
This pricing
term sheet (the Pricing Term Sheet) is qualified in its entirety by reference to Zimmer Biomet Holdings, Inc.s preliminary prospectus supplement, dated November 8, 2019 (the Preliminary Prospectus
Supplement). The information in this Pricing Term Sheet supplements the information in the Preliminary Prospectus Supplement and supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the
information in the Preliminary Prospectus Supplement. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Preliminary Prospectus Supplement.
|
|
|
Issuer:
|
|
Zimmer Biomet Holdings, Inc. (the Company)
|
|
|
Issuer Legal Entity Identifier:
|
|
2P2YLDVPES3BXQ1FRB91
|
|
|
Offering Format:
|
|
SEC Registered
|
|
|
Title of Securities:
|
|
500,000,000 1.164% Notes due 2027 (the Notes)
|
|
|
Principal Amount:
|
|
500,000,000
|
|
|
Maturity Date:
|
|
November 15, 2027
|
|
|
Coupon:
|
|
1.164%
|
|
|
Yield to Maturity:
|
|
1.164%
|
|
|
Benchmark German Government Security:
|
|
DBR 0.500% due August 15, 2027
|
|
|
Benchmark German Government Security Price; Yield:
|
|
107.14%; -0.404%
|
|
|
Spread to Benchmark German Government Security:
|
|
+156.8 basis points
|
|
|
Benchmark Mid-Swap:
|
|
8-year Mid-Swap
|
|
|
Benchmark Mid-Swap Yield:
|
|
0.014%
|
|
|
Spread to Benchmark Mid-Swap Yield:
|
|
+115 basis points
|
|
|
Interest Payment Date:
|
|
Annually in arrears on November 15 of each year, commencing on November 15, 2020
|
|
|
Date Count Convention:
|
|
ACTUAL/ACTUAL (ICMA)
|
1
|
|
|
|
|
Redemption Provisions:
|
|
The Company may redeem the Notes at its option, either in whole at any time or in part from time to time prior to September 15, 2027, at
a redemption price equal to the greater of (i) 100% of the principal amount of the Notes being redeemed and (ii) the sum of the present values of the Remaining Scheduled Payments on the Notes being redeemed, discounted to the date of redemption
on an annual basis at the applicable Comparable Government Bond Rate plus 25.0 basis points, plus accrued and unpaid interest on the Notes being redeemed to, but excluding, the redemption date.
The Company may redeem all or part of the Notes at any time or from time to time on and
after September 15, 2027, at the Companys option, at a redemption price equal to 100% of the principal amount of the Notes being redeemed, plus accrued and unpaid interest thereon to, but excluding, the redemption date.
In the event that certain developments affecting United States taxation would cause the
Company to pay additional amounts with respect to the Notes as described under the caption Description of the NotesTax Redemption in the Preliminary Prospectus Supplement, the Company may, at any time at its option, redeem the
Notes, in whole but not in part, at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest thereon to, but excluding, the date fixed for redemption.
|
|
|
Repurchase at the Option of Holders upon a Change of Control Repurchase Event:
|
|
If a Change of Control Repurchase Event occurs with respect to the Notes, the Company will be required to offer to repurchase the Notes at a repurchase price equal to 101% of their principal amount, plus accrued and unpaid interest
on the Notes to be repurchased to the date of repurchase, unless the Notes have been previously redeemed or called for redemption.
|
|
|
Price to Public:
|
|
100.00%
|
|
|
Aggregate Gross Proceeds:
|
|
500,000,000
|
|
|
Underwriting Discount:
|
|
40.0 basis points
|
|
|
Aggregate Net Proceeds (Before Expenses):
|
|
498,000,000
|
|
|
Trade Date:
|
|
November 8, 2019
|
|
|
Settlement Date*:
|
|
November 15, 2019 (T+5)
|
|
|
Minimum Denominations:
|
|
100,000 and integral multiples of 1,000 in excess thereof
|
|
|
CUSIP:
|
|
98956P AR3
|
|
|
ISIN:
|
|
XS2079105891
|
|
|
Common Code:
|
|
207910589
|
|
|
Ratings**:
|
|
Baa3 (Moodys) / BBB (S&P)
|
|
|
Form of Notes:
|
|
One or more global notes deposited with, or on behalf of, Elavon Financial Services DAC, or a nominee thereof, as common depositary for Clearstream and Euroclear.
|
|
|
Joint Book-Running Managers:
|
|
BNP Paribas
J.P. Morgan Securities plc
MUFG Securities EMEA plc
SMBC Nikko Capital Markets
Limited
|
2
|
|
|
|
|
Senior Co-Managers:
|
|
Bank of Montreal, London Branch
Credit Suisse
Securities (Europe) Limited
DNB Markets, Inc.
Mizuho
International plc
|
|
|
Co-Managers:
|
|
Citigroup Global Markets Limited
DZ Financial
Markets LLC
Goldman Sachs & Co. LLC
HSBC Securities
(USA) Inc.
Merrill Lynch International
PNC Capital Markets
LLC
RBC Europe Limited
Siebert Williams Shank & Co.,
LLC
The Toronto-Dominion Bank
UniCredit Bank AG
U.S. Bancorp Investments, Inc.
Wells Fargo Securities
International Limited
|
|
|
Expected Listing:
|
|
The Company will use its reasonable efforts to list the Notes on the New York Stock Exchange. The listing application will be subject to approval by the New York Stock Exchange. If the application is approved, trading of the Notes
on the New York Stock Exchange is expected to begin within 30 days of the original issue date of the Notes. If such a listing is obtained, the Company will have no obligation to maintain such listing and may delist the Notes at any time.
|
|
|
Target Market (MiFID II Product Governance):
|
|
Eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail in EEA.
|
* The Company expects to deliver the Notes against payment therefor on or about November 15, 2019, which is the fifth
London business day following the date of the pricing of the Notes (such settlement cycle being referred to as T+5). Under the EU Central Securities Depositaries Regulation, trades in the secondary market generally are required to
settle in two London business days unless the parties to such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes earlier than the second London business day before November 15, 2019 will be required, by virtue
of the fact that the Notes initially will settle T+5, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement, and so should consult their own advisors.
** An explanation of the significance of ratings may be obtained from the rating agencies. Generally, rating agencies base their ratings on such material and
information, and such of their own investigations, studies and assumptions, as they deem appropriate. Each rating of the Notes should be evaluated independently of any other rating and of similar ratings of other securities. A credit rating of a
security is not a recommendation to buy, sell or hold securities and may be subject to review, revision, suspension, reduction or withdrawal at any time by the assigning rating agency.
This Pricing Term Sheet supplements the Preliminary Prospectus Supplement issued by the Company on November 8, 2019 relating to its prospectus dated
February 26, 2019, Registration Statement No. 333-229882.
The Company has filed a registration
statement (including a base prospectus) and the Preliminary Prospectus Supplement with the U.S. Securities and Exchange Commission (the SEC) for the offering to which this communication relates. Before you invest, you should read the
Preliminary Prospectus Supplement, the final prospectus supplement (when available) and the accompanying base prospectus in that registration statement and other documents the Company has filed with the SEC for more complete information about the
Company and this offering. You may obtain these documents for free by visiting EDGAR on the SECs website at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the
Preliminary Prospectus Supplement, the final prospectus supplement (when available) and the accompanying base prospectus if you request it by calling BNP Paribas at 1-800-854-5674, J.P. Morgan Securities plc collect at +44-207-134-2468, MUFG
Securities EMEA plc at +44-20-7577-2228 and SMBC Nikko Capital Markets Limited at +44-203-527-7552.
3
Zimmer Biomet (NYSE:ZBH)
Historical Stock Chart
From Feb 2024 to Mar 2024
Zimmer Biomet (NYSE:ZBH)
Historical Stock Chart
From Mar 2023 to Mar 2024